MINI-REVIEW ARTICLE

Cardiac MRI in Autoimmune Diseases: Where Are We Now?

Natalia G. Vallianou1*, Eleni Geladari1, Fotis Panagopoulos1 and Maria Kalantzì2

1Department of Internal Medicine, Evangelismos General Hospital, 45-47 Ipsilantou Str., 10676, Athens, Greece; 2Department of Radiology and Cardiology, Iaso General Hospital, Athens, Greece

Abstract: Cardiovascular magnetic resonance imaging (CMR) allows the early diagnosis of various cardiovascular pathophysiologic phenomena in autoimmune diseases. Preliminary studies suggest that CMR holds a promising role in initiating the necessary changes in anti-rheumatic and cardiac treatment among patients with autoimmune diseases and cardiovascular diseases (CVD). It is widely known that the presence of late gadolinium enhancement (LGE) has been related to a worse cardiovascular prognosis. CMR has been documented to be the most valuable tool for diagnosis and risk prediction of cardiac involvement in a sarcoidosis population, while in SLE, the gap between clinical and autopsy diagnosis of the myocardial disease could be narrowed with the implementation of CMR. In different connective tissue diseases, including SLE, LGE has been demonstrated to be present early after the initial diagnosis of SLE. Considering that CMR, including LGE identifies more patients with silent myocardial disease in SLE and other connective tissue diseases than echocardiography, CMR should be the preferred imaging modality, especially in the era of modern techniques with broader availability and expertise. In this review, we summarize the major indications, advantages and limitations of the use of CMR among patients with autoimmune disorders.

Keywords: Autoimmune disorders, cardiac magnetic resonance (CMR), late gadolinium enhancement (LGE), early gadolinium enhancement (EGE), cardiac MRI, EGPA.

1. INTRODUCTION

Autoimmune rheumatic diseases are associated with a high incidence of cardiovascular diseases (CVD) [1]. Until today, CVD is often underestimated in patients with rheumatic diseases because usually, rheumatologists focus on the signs and symptoms of the systemic disease. Although the various treatment modalities have resulted in reducing disease-related mortality, life expectancy in people with autoimmune diseases remains lower compared to the general population, and cardiovascular involvement mainly accounts for this fact [2-7]. CVD in rheumatic diseases is the result of various pathophysiologic mechanisms, including myocardial, inflammatory, ischemic, and fibrotic changes [8, 9]. No matter the pathophysiologic background, the symptoms of heart involvement are usually subtle and indolent; thus, they are usually underestimated. In general, the development of clinically overt cardiac signs is equal to advanced cardiac disease and carries a poor prognosis [10].

Cardiovascular magnetic resonance imaging (CMR) allows the early diagnosis of various cardiovascular pathophysiologic phenomena in autoimmune diseases [11, 12]. Preliminary studies suggest that CMR holds a promising role in initiating the necessary changes in anti-rheumatic and cardiac treatment among patients with autoimmune diseases and CVD [13, 14].

2. DIAGNOSTIC ROLE OF CMR

EGPA (Eosinophilic Granulomatosis with Polyangiitis, formerly known as Churg-Strauss syndrome) and GPA (Granulomatosis with Polyangiitis, formerly known as Wegener’s granulomatosis) are both subtypes of ANCA-associated vasculitides. The prevalence of myocardial involvement varies, ranging from 16 to 92% in EGPA and 6 to 86% in GPA patients, depending on different diagnostic methods and disease activity [15]. Patients with myocardial involvement may have no or nonspecific symptoms, normal ECG, and preserved left-ventricular ejection fraction (LV-EF); yet, they may nevertheless face life-threatening arrhythmia or end-stage heart failure during the course of the disease [16, 17]. EGPA patients frequently show myocardial granulomas and severe tissue alterations on histopathology, and up to 50% of patients die of cardiac causes [18, 19]. This is also true in GPA patients [20]. Since myocardial involvement might be reversible if prompt, adequate treatment is initiated, a reliable tool for the early detection of myocardial involvement is warranted [21]. Cardiovascular magnetic resonance (CMR) offers not only functional assessment but also excellent tissue characterization by the use of late gadolinium enhancement (LGE) [22]. However, LGE is known to perform best in the detection of focal myocardial processes rather than diffuse fibrotic or inflammatory processes [23].

CMR contributes to the diagnosis of myocarditis by mainly using three types of images: T2-weighted (T2-W), early T1-weighted: early gadolinium enhancement (EGE) images taken 1 min and late gadolinium enhancement (LGE) images...
Since native T1, ECV, and T2 values were independent of tides, which might have been missed otherwise [46, 47]. Therefore, potentially reversible stages of ANCA-associated vasculitis, had normal ECG, and a preserved LV-EF, therefore might be appropriate tools to complement LGE-mapping techniques. Interestingly, most patients were non- or oligosymptomatic, had normal ECG, and a preserved LV-EF, and GPA show several abnormalities detected by CMR mapping seem to be appropriate techniques since a combination of both inflammation and fibrosis could be detected by histology in other studies with AAV patients [3, 25].

Currently, the most commonly employed noninvasive imaging modality used in cardiovascular imaging is echocardiography, due to its high availability, portability, low cost, lack of ionizing radiation exposure, and high expertise among cardiologists [40-44]. It can reliably identify morphological, functional, and valvular alterations both at rest and stress; however, image quality is strongly dependent on the acoustic window of the patient and the expertise of the operator. Furthermore, classic echocardiographic indexes do not address the aforementioned necessity for cardiac tissue characterization [44, 45]. Transthoracic echocardiography using classical and novel ultrasound techniques such as tissue Doppler imaging and speckle tracking in an SLE population documented that systolic longitudinal and diastolic performance impairments were frequent findings in SLE patients without overt CVD [46, 47]. Although these advanced echocardiographic techniques provided more details about the cardiovascular background in auto-immune rheumatic diseases (ARDs), they could not define the exact nature of myocardial lesions in patients with preserved diastolic or systolic function, as is often the case in ARDs patients [48, 49]. Their role is thus restricted to the detection of changes based on serial evaluations of the same patient; however, clear documentation of edema, fibrosis, perfusion defects, or necrosis is of paramount importance for risk stratification of ARDs patients, cannot be obtained [49-51].

3. PROGNOSTIC ROLE OF CMR

3.1. The Potential of LGE in Risk Stratification of Rheumatic Diseases

LGE has a low prevalence in a middle-aged population at low- or intermediate risk, estimated to be around 0.7% [52]. It is widely known that the presence of LGE has been related to a worse cardiovascular prognosis [53-55]. For ex-
ample, in sarcoidosis, the presence of LGE has been related to a significantly increased risk of cardiovascular morbidity and mortality [56, 57]. CMR has been documented to be the most valuable tool for diagnosis and risk prediction of cardiac involvement in a sarcoidosis population (Fig. 1) [57]. In SLE, the gap between clinical and autopsy diagnosis of the myocardial disease could be narrowed with the implementation of CMR, when comparing 30% of LGE in a recently published cohort by Burkardt et al., with an approximately 40% myocardial involvement observed in autopsy studies [58, 59]. In different connective tissue diseases, including SLE, LGE has been demonstrated to be present early after the initial diagnosis of SLE (Figs. 2 and 3) [58]. Considering that CMR, including LGE identifies more patients with silent myocardial disease in SLE and other connective tissue diseases than echocardiography, CMR should be the preferred imaging modality, especially in the era of modern techniques with broader availability and expertise [58, 59]. Since there have not been any good clinical parameters to predict myocardial disease in SLE patients yet, LGE in CMR might provide this potential. The increasing extend of LGE is related to poorer outcomes among patients with cardiomyopathies of another origin. However, data comparing SLE patients with and without LGE are scarce [58, 59].

Regarding rheumatoid arthritis patients, subclinical CVD has been documented, with focal and diffuse myocardial fibrosis and inflammation, findings which have been related to myocardial strain and rheumatoid arthritis disease activity [25].

Fig. (1). Cardiac sarcoidosis in a 38-year-old man. Short axis T2W STIR (a) and LGE (b) images. Thickening of the RV free and inferior wall showing an increased signal intensity representing cardiac inflammation. Late imaging shows enhancement of the same areas.

Fig. (2). A short axis Late Gadolinium Enhancement (LGE) image of a female patient with dermatomyositis shows enhancement of the interventricular septum (at the RV side). Also, note the presence of pericardial effusion.

Fig. (3). Short (a) and horizontal long (b) axis Late Gadolinium Enhancement (LGE) images of a female patient with lupus show enhancement involving the interventricular septum (at the RV side), the inferior and the lateral wall (mostly at the sub-epicardium).
CMR has been proved useful in detecting cardiac involvement in patients with systemic sclerosis, even in the absence of cardiac symptoms, such as in cases of chronic myocardial inflammation and focal and diffuse myocardial fibrosis [60]. Besides, CMR has documented that the pattern of myocardial fibrosis in 105 patients with systemic sclerosis and Q waves has been due to the systemic disease and not to coronary artery disease [61].

### Table 1. Proposing the performance of CMR in various autoimmune disorders, according to Mavrogeni et al., [58].

| When to CMR?                                                                 | Why?                                                                 |
|-----------------------------------------------------------------------------|----------------------------------------------------------------------|
| There is a plan to change treatment, especially if biological agents are to be administered | Use with caution in patients with heart failure due to the risk of HF or MI due to anti-TNFα treatment |
| Arrhythmia                                                                  | Could indicate cardiomyopathy                                        |
| Increases in troponin, brain natriuretic peptide or D-dimers                | Could indicate cardiomyopathy or pulmonary embolism                  |
| Newly onset of heart failure                                                | Could indicate cardiomyopathy                                        |
| The patient is complaining of cardiac symptoms, and the routine cardiac evaluation is normal | Indolent cardiomyopathy could be unraveled                            |
| There is a mismatch between clinical and laboratory findings               | Indolent cardiomyopathy could be unraveled                            |
| The patient is being treated with hydroxychloroquine or biologic agents    | Hydroxychloroquine may cause cardiomyopathy, and anti-TNFα may exacerbate HF or MI |

Coronary artery disease has turned out to be a major cause of morbidity and mortality among SLE patients; therefore, SLE patients with the highest risk of CVD adverse events should be identified early in the course of the disease [57-59]. In the study by Burkardt et al., repolarisation abnormalities, hypertension, renal disorders together with larger left ventricular end-diastolic volumes were more common among patients with stress-perfusion deficits [59]. Since clinical symptoms were unspecific, the above-mentioned parameters, which were easy to detect, have to be particularly evaluated and valued for the presence or not of coronary artery disease in SLE patients in the future. Attention should be drawn to the various ECG abnormalities. A previous study has associated ECG abnormalities of Q-waves in the inferior leads with CMR abnormalities, representing acute myocarditis, past myocarditis or past myocardial infarction with the use of CMR, including LGE, but without stress perfusion imaging [57]. An algorithm for the CVD work-up of SLE patients has only recently been suggested by Mavrogeni et al., (Table 1) [58]. In this algorithm, echocardiography remains the cornerstone for non-invasive techniques for the assessment of CVD involvement as it is inexpensive, widely available and can guide further workup, especially in the acute clinical setting. CMR has been highlighted as a preferred imaging modality in SLE patients with no CVD symptoms or in oligo-symptomatic patients, when ECG or echocardiography was abnormal and in not acutely symptomatic patients, ie under circumstances where additional clinical or laboratory features were present e.g. ECG abnormalities or inflammatory biomarkers. In these situations, CMR would be a wonderful tool for further diagnostic evaluation and treatment and could, as well, reduce exposure to radiation. The Achilles’ heel of CMR remains the lower availability and the higher costs [59, 60]. Nevertheless, in the asymptomatic or oligo-symptomatic SLE patient, results of the CMR could rule out structural cardiovascular disease or could prompt for the necessity of further evaluation, such as with coronary angiography [61]. Apart from coronary angiography, which has a stable place in diagnosing coronary artery disease, another imaging modality that has recently gained attention is 18-FDG-PET/CT scan, which may detect cancer among patients with autoimmune disorders. It has been demonstrated that 18-FDG-PET/CT may differentiate between cancer and inflammation in patients with systemic immune diseases [62]. Its value regarding cardiac imaging has to be further elucidated in future large-scale studies.

**CONCLUSION**

In conclusion, echocardiography is an inexpensive, bedside, and widely available tool that can help the diagnosis in the appropriate clinical setting. However, its sensitivity is questionable for the diagnosis of subtle disease among patients with autoimmune rheumatic diseases. Currently, CMR seems to be a valuable solution in finding answers regarding tissue characterization, disease acuity, and prediction in these patients. MRI is surely a very useful tool in rheumatic disease, but most data are observational and there is not much evidence yet that MRI can help to guide treatment and management. Nevertheless, it could define the timely initiation of prompt treatment in patients with autoimmune diseases and could help to change their prognosis.

**CONSENT FOR PUBLICATION**

Not applicable.

**FUNDING**

None.

**CONFLICT OF INTEREST**

The authors have no conflicts of interest, financial or otherwise.

**ACKNOWLEDGEMENTS**

Declared none.

**REFERENCES**

[1] Pohl D, Benseler S. Systemic inflammatory and autoimmune disorders. Handb Clin Neurol 2013; 112: 1243-52. http://dx.doi.org/10.1016/B978-0-444-52910-7.00047-7  PMID: 23622335
[2] Avilia-Zubieta JA, Choi HK, Sadatsafavi M, Etminan M, Esdaile JM, Lacaille D. Risk of cardiovascular mortality in patients with rheumatoid arthritis: a meta-analysis of observational studies. Arthritis Rheum 2008; 59(12): 1690-7. http://dx.doi.org/10.1002/art.24092 PMID: 19035419
[3] Sherer Y, Shoefeld Y. Mechanisms of disease: atherosclerosis in
autoimmune diseases. Nat Clin Pract Rheumatol 2006; 2(2): 99-106.  
http://dx.doi.org/10.1038/ncprheum0092 PMID: 16932663

[4] Kitas GD, Gabriel SE. Cardiovascular disease in rheumatoid arthritis: state of the art and future perspectives. Ann Rheum Dis 2011; 70(1): 8-14.  
http://dx.doi.org/10.1136/ard.2010.142133 PMID: 21105513

[5] Hollar I, Meroni PL, Ahearn JM, et al. Cardiovascular disease in autoimmune rheumatic diseases. Autoimmun Rev 2013; 12(10): 1004-15.  
http://dx.doi.org/10.1016/j.autrev.2013.03.013 PMID: 23541482

[6] Björnäld L, Yin L, Granath F, Klarskjö L, Ekbom A. Cardiovascular disease a hazard despite improved prognosis in patients with systemic lupus erythematosus: results from a Swedish population based study 1964-95. J Rheumatol 2004; 31(4): 713-9.  
PMID: 15088296

[7] Symmons DP, Gabriel SE. Epidemiology of CVD in rheumatic disease, with a focus on RA and SLE. Nat Rev Rheumatol 2011; 7(9): 399-408.  
http://dx.doi.org/10.1038/nrrheum.2011.75 PMID: 21629241

[8] Gasparian AY. Cardiovascular risk and inflammation: pathophysiological mechanisms, drug design, and targets. Curr Pharm Des 2012; 18(11): 1447-9.  
http://dx.doi.org/10.2174/138161212799504777 PMID: 22364139

[9] Neumann T, Manger B, Schmid M, et al. Multimodality assessment of cardiac involvement in Churg-Strauss syndrome patients in clinical remission. Circ J 2011; 75(3): 649-55.  
http://dx.doi.org/10.1253/circj.CJ-10-0772 PMID: 21139253

[10] Al-Dhaher FF, Pope JE, Ouimet JM. Determinants of morbidity and mortality of systemic sclerosis in Canada. Semin Arthritis Rheum 2010; 39(4): 269-77.  
http://dx.doi.org/10.1016/j.semarthritis.2008.06.002 PMID: 18706680

[11] Mavrogeni SI, Sifakis PP, Dimitroulas T, et al. Can cardiovascular magnetic resonance prompt early cardiovascular/rheumatic treatment in autoimmune rheumatic diseases? Current practice and future perspectives. Rheumatol Int 2018; 38(6): 949-58.  
http://dx.doi.org/10.1007/s00296-018-4004-6 PMID: 29516170

[12] Mavrogeni SI, Sifakis PP, Markoussis-Mavrogenis G, et al. Cardiovascular magnetic resonance imaging pattern in patients with autoimmune rheumatic diseases and ventricular tachycardia with preserved ejection fraction. Int J Cardiol 2019; 284: 105-48.  
http://dx.doi.org/10.1016/j.ijcard.2016.04.158 PMID: 27179903

[13] Mavrogeni SI, Sifakis PP, Koutsogeorgopoulou L, et al. Cardiac tissue characterization and imaging in autoimmune rheumatic diseases. JACC Cardiovasc Imaging 2017; 10(11): 1387-96.  
http://dx.doi.org/10.1016/j.jcmg.2017.08.017 PMID: 29122140

[14] Hazebrook MR, Kemna MJ, Schalla S, et al. Prevalence and prognostic relevance of cardiac involvement in ANCA-associated vasculitis: eosinophilic granulomatosis with polyangiitis and granulomatosis with polyangiitis. Int J Cardiol 2015; 199: 170-9.  
http://dx.doi.org/10.1016/j.ijcard.2015.06.087 PMID: 26209947

[15] Marmursztejn J, Guillevin L, Trebossen R, et al. Churg-Strauss syndrome cardiac involvement evaluated by cardiac magnetic resonance imaging in Churg-Strauss syndrome related cardiac involvement. A case report of three patients and literature review. Rev Med Interne 2010; 31(9): 600-5.  
http://dx.doi.org/10.1016/j.revmed.2010.04.009 PMID: 20605285

[16] Neumann T, Manger B, Schmid M, et al. Cardiac involvement in Churg-Strauss syndrome: impact of endomyocarditis. Medicine (Baltimore) 2009; 88(4): 236-43.  
http://dx.doi.org/10.1097/MD.0b013e3181f5a5 PMID: 19593229

[17] Vignaux O, Marmurzstejn J, Cohen P, et al. [Cardiac imaging in ANCA-associated vasculitis]. Presse Med 2007; 36(5 Pt 2): 902-6.  
http://dx.doi.org/10.1016/j.pmed.2007.02.013 PMID: 17360146

[18] Raman SV, Aneja A, Jarjour WM. CMR in inflammatory vasculitis. J Cardiovasc Magn Reson 2012; 14: 82.  
http://dx.doi.org/10.1186/1532-429X-14-82 PMID: 23199343

[19] Szczeklik W, Miszalski-Janika T, Mastalerz L, et al. Multimodality assessment of cardiac involvement in Churg-Strauss syndrome patients in clinical remission. Circ J 2011; 75(3): 649-55.  
http://dx.doi.org/10.1253/circj.CJ-10-0772 PMID: 21139253

[20] Vinit J, Bielefeld P, Muller G, et al. Heart involvement in Churg-Strauss syndrome: retrospective study in French Burgundy population in past 10 years. Eur J Intern Med 2010; 21(4): 341-6.  
http://dx.doi.org/10.1016/j.ejim.2010.05.004 PMID: 20603049

[21] Wassmuth R, Göbel U, Natusch A, et al. Cardiovascular magnetic resonance imaging detects cardiac involvement in Churg-Strauss syndrome. J Card Fail 2008; 14(10): 856-60.  
http://dx.doi.org/10.1016/j.cardfail.2008.07.227 PMID: 19041050

[22] Chen W, Griss TM, Kang S, Warner TF, Christian TF. Images in cardiovascular medicine. Infiltrative eosinophilic myocarditis diagnosed and localized by cardiac magnetic resonance imaging. Circulation 2004; 110(3): e19.  
http://dx.doi.org/10.1161/01.CIR.0000135586.94417.3C PMID: 15262855

[23] Petersen SE, Kardos A, Neubauer S. Subendocardial and papillary muscle involvement in a patient with Churg-Strauss syndrome, detected by contrast enhanced cardiovascular magnetic resonance imaging. Heart 2005; 91(1): e9.  
http://dx.doi.org/10.1136/hrt.2004.050700 PMID: 15604316

[24] Puttmann VO, D′Cruz D, Smith Z, et al. Native myocardial T1 mapping by cardiovascular magnetic resonance imaging in subclinical cardiomyopathy in patients with systemic lupus erythematosus. Circ Cardiovasc Imaging 2013; 6(2): 295-301.  
http://dx.doi.org/10.1161/CIRCIMAGING.112.001515 PMID: 23403334
to histology and molecular pathology. Circulation 2004; 109(10): 1250-8. http://doi.org/10.1161/01.CIR.0000118493.13323.81 PMID: 14993139

[50] Weir-McCall JR, Fitzgerald K, Papagiopoulou CJ, et al. Prevalence of unrecognized myocardial infarction in a low-intermediate risk asymptomatic cohort and its relation to systemic atherosclerosis. Eur Heart J Cardiovasc Imaging 2017; 18(6): 657-62. PMID: 27550660

[51] Kwong RY, Chan AK, Brown KA, et al. Impact of unrecognized myocardial scar detected by cardiac magnetic resonance imaging on event-free survival in patients presenting with signs or symptoms of coronary artery disease. Circulation 2006; 113(23): 2733-43. http://doi.org/10.1161/CIRCULATIONAHA.105.570648 PMID: 16754804

[52] Kwong RY, Sattar H, Wu H, et al. Incidence and prognostic implication of unrecognized myocardial scar characterized by cardiac magnetic resonance in diabetic patients without clinical evidence of myocardial infarction. Circulation 2008; 118(10): 1011-20. http://doi.org/10.1161/CIRCULATIONAHA.107.727826 PMID: 18725488

[53] Wu KC, Weiss RG, Thiemann DR, et al. Late gadolinium enhancement by cardiovascular magnetic resonance heralds an adverse prognosis in nonischemic cardiomyopathy. J Am Coll Cardiol 2008; 51(25): 2414-21. http://doi.org/10.1016/j.jacc.2008.03.018 PMID: 18565399

[54] Coleman GC, Shaw PW, Balfour PC Jr, et al. Prognostic value of myocardial scarring on CMR in patients with cardiac sarcoidosis. JACC Cardiovasc Imaging 2017; 10(4): 411-20. http://doi.org/10.1016/j.jcmg.2016.05.009 PMID: 27450877

[55] Kouranos V, Tzelipos GE, Rapti A, et al. Complementary role of CMR to conventional screening in the diagnosis and prognosis of cardiac sarcoidosis. JACC Cardiovasc Imaging 2017; 10(12): 1437-47. http://doi.org/10.1016/j.jcmg.2016.11.019 PMID: 28330653

[56] Mavrogenis G, Koutsogeorgopoulou L, Mavrogeni S, Markoussis-Mavrogenis G, Koutsogeorgopoulou L, et al. Cardiovascular magnetic resonance imaging pattern at the time of diagnosis of treatment naïve patients with connective tissue disease. J Am Coll Cardiol 2018; 71(10): 1129-41. http://doi.org/10.1016/j.jacc.2017.12.073 PMID: 29579201

[57] Mavrogenis G, Kolovou G. Complementary role of cardiovascular magnetic resonance imaging in rheumatoid arthritis: insights from CMR T1 mapping. JACC Cardiovasc Imaging 2015; 8(5): 526-36. http://doi.org/10.1016/j.jcmg.2014.12.025 PMID: 25980584

[58] Bohnen S, Radunski UK, Lund GK, et al. Performance of t1 and t2 mapping cardiovascular magnetic resonance to detect active myocarditis in patients with recent-onset heart failure. Circ Cardiovasc Imaging 2015; 8(6): 6. http://doi.org/10.1016/j.circimaging.2015.01.029 PMID: 26015267

[59] Mavrogeni S, Koutsogeorgopoulou L, Dimitroulas T, et al. Combined brain/heart magnetic resonance imaging in systemic lupus erythematosus. Curr Cardiol Rev 2020; 16(3): 178-86. http://doi.org/10.2174/1573403X1573403X190801122105 PMID: 31368877

[60] Mavrogeni S, Spargias K, Markoussis V, et al. Myocardial inflammation in autoimmune diseases: investigation by cardiovascular magnetic resonance and endomyocardial biopsy. Inflamm Allergy Drug Targets 2009; 8(5): 390-7. http://doi.org/10.2174/187152810980502540 PMID: 20025587

[61] Mavrogeni S, Papadopoulos G, Karanasios E, Kokkinos DV. “Cardiovascular magnetic resonance imaging reveals myocardial inflammation and coronary artery ectasia during the acute phase of Kawasaki disease”. Int J Cardiol 2009; 136(3): e51-3. http://doi.org/10.1016/j.ijcard.2008.05.005 PMID: 18667250

[62] Mavrogeni S, Markoussis-Mavrogenis G, Heutemann D, van Wijk K, Reiber HJ, Kolovou G. “How many times must a man look up before he can really see the sky?” Rheumatic cardiovascular disease in the era of multimodality imaging. World J Methodol 2015; 5(3): 136-43. http://doi.org/10.5662/wjm.v5.i3.136 PMID: 26413486

[63] Mavrogeni S, Dimitroulas T, Gabriel S, Sifikakis PP, Phostom GM, Kitas GD. Why currently used diagnostic techniques for heart failure in rheumatoid arthritis are not enough: the challenge of cardiovascular magnetic resonance imaging. Rev Cardiovasc Med 2014; 15(4): 320-31. PMID: 25662926

[64] Mavrogeni S, Schwitter J, van Rossum A, et al. Cardiac magnetic resonance imaging in myocardial inflammation in autoimmune rheumatic diseases: An appraisal of the diagnostic strengths and limitations of the Lake Louise criteria. Int J Cardiol 2018; 252: 216-9. http://doi.org/10.1016/j.ijcard.2017.11.032 PMID: 29156571

[65] Guşetü G, Pop D, Pamlit C, et al. Subclinical myocardial impairment in SLE: insights from novel ultrasound techniques and clinical determinants. Med Ultrason 2016; 18(1): 47-56. http://doi.org/10.11152/mu.2013.2066.181 PMID: 26962554

[66] Marsan NA, Tops LF, Nihoyannopoulos P, Holman ER, Bax JJ. Real-time three dimensional echocardiography: current and future clinical applications. Heart 2009; 95(22): 1881-90. http://doi.org/10.1136/hrt.2008.151613 PMID: 19873575

[67] Thiele H, Kappel MJ, Conradt S, Niehauer J, Hambrecht R, Schuler G. Reproducibility of chronic and acute infarct size measurement by delayed enhancement-magnetic resonance imaging. J Am Coll Cardiol 2006; 47(8): 1641-5. http://doi.org/10.1016/j.jacc.2005.11.065 PMID: 16631003

[68] De Cobelli F, Pieroni M, Espósito A, et al. Delayed gadolinium- enhanced cardiac magnetic resonance in patients with chronic myocarditis presenting with heart failure or recurrent arrhythmias. J Am Coll Cardiol 2006; 47(8): 1649-54. http://doi.org/10.1016/j.jacc.2005.11.067 PMID: 16631005

[69] Mahrholdt H, Goedecke C, Wagner A, et al. Cardiovascular magnetic resonance assessment of human myocarditis: a comparison ...